Drug Manufacturers: Dynavax Technologies (NASDAQ:DVAX), Pernix Therapeutics Holdings (NASDAQ:PTX), Endo International PLC (NASDAQ:ENDP), ISIS Pharmaceuticals, (NASDAQ:ISIS), Teva Pharmaceutical Industries (NYSE:TEVA)

JMP Securities lowered shares of Dynavax Technologies Corporation (NASDAQ:DVAX), from an outperform rating to a market perform rating in a report released on Monday, Stock Ratings Networkreports. JMP Securities currently has $2.50 price objective on the stock. Dynavax Technologies Corporation (NASDAQ:DVAX), weekly performance is 1.89%. On last trading day company shares ended up $1.62. Analysts mean target price for the company is $5.00. Dynavax Technologies Corporation (NASDAQ:DVAX), distance from 50-day simple moving average (SMA50) is 9.59%.

On June 23, 2014, Pernix Therapeutics Holdings, Inc. (“Pernix” or the “Company”) (NASDAQ MKT: PTX), a specialty pharmaceutical company, announced the appointment of Sanjay Patel as Chief Financial Officer. Pernix Therapeutics Holdings Inc (NASDAQ:PTX), fell 1.85% in last trading session and ended the day on $9.00. PTX, Gross Margin is 5.20% and its return on assets is -11.20%. Pernix Therapeutics Holdings Inc (NASDAQ:PTX), quarterly performance is 65.44%.

Summer Street reissued their buy rating on shares of Endo International PLC (NASDAQ:ENDP), in a research report released on Thursday morning. Endo International PLC (NASDAQ:ENDP), shares moved down 0.45% in last trading session and was closed at $70.34, while trading in range of $70.23 – 71.90. Endo International PLC (NASDAQ:ENDP), year to date (YTD) performance is 4.27%.

ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS), SVP C Frank Bennett sold 11,200 shares of the stock on the open market in a transaction that occurred on Monday, June 23rd. The shares were sold at an average price of $36.78, for a total value of $411,936.00. Following the transaction, the senior vice president now directly owns 4,336 shares of the company’s stock, valued at approximately $159,478. ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS),ended the last trading day at $35.44. Company weekly volatility is calculated as 3.77% and price to cash ratio as 6.00. ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS),showed a negative weekly performance of 3.33%.

Analysts at Wells Fargo & Co. began coverage on shares of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), in a research report issued to clients and investors on Tuesday. The firm set a “market perform” rating on the stock. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), net profit margin is 6.80% and weekly performance is -0.26%. On last trading day company shares ended up $52.83. Analysts mean target price for the company is $57.09. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), distance from 50-day simple moving average (SMA50) is 4.05%.